Viewing data from:

VISTIDE

NDA

CIDOFOVIR | N020638 | GILEAD SCIENCES INC

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

API Supply Chain3 active DMFs1 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

EMCURE PHARMACEUTICALS LTDCIDOFOVIR USP

DMF 244102010

JINAN JINDA PHARMACEUTICAL CHEMISTRY CO LTDCIDOFOVIR DIHYDRATE

DMF 254062011

NATCO PHARMA LTDCIDOFOVIR DIHYDRATE USP

DMF 385932023

ALP PHARM BEIJING CO LTDInactiveCIDOFOVIR DIHYDRATE

DMF 234462010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 375MG BASE/5ML (EQ 75MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

0 patents0 exclusivities▴

SOLUTION;INTRAVENOUS | Approved: Jun 26, 1996

No patent or exclusivity listings for this strength.